Compare DexCom, Inc. (DXCM) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Logitech International SA — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Logitech International SA trades at $99.36 (market cap $14.35B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Logitech International SA pays a 1.7% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LOGI | |
|---|---|---|
Market Cap | $28.06B | $14.35B |
Sector | Health | Technology |
52-Week High | $89.53 | $126.69 |
52-Week Low | $54.84 | $85.84 |
Enterprise Value | $27.03B | $12.69B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Logitech (LOGI) trades at $100.59, down 1.59% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a 20.81 P/E ratio and robust profitability, including a 14.69% net income margin and 32.78% ROE. Recent earnings beats and a partnership with Call of Duty: Modern Warfare 4 highlight growth momentum, while cash flow trends indicate operational strength despite a slight net outflow in 2025.
The outlook is mixed: analyst consensus targets $113.00 with 26% buy ratings, but technical resistance near $102 poses near-term challenges. Risks include competitive pressures and market volatility, though B2B and AI product expansion offers upside. The stock presents a balanced opportunity for growth-focused investors amid cautious sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
